|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
C3b Complement Assay Report
Test Code11371
CPT Codes
83520<br>This test is not available for New York patient testing<br>Restricted Client Code
Preferred Specimen
2 mL serum collected in a red-top tube (no gel)
Patient Preparation
PLEX treatments will affect serum tests, please wait approximately 14 days after PLEX to draw samples.
Minimum Volume
2 mL
Instructions
Serum samples MUST be processed and frozen down to -80° C immediately after collection (please see instructions).
Sample type must be clearly labeled "serum" and shipped out overnight on at least 5 lbs dry ice (Monday-Thursday).
1.) Follow standard phlebotomy techniques to collect at least 6 cc of whole blood drawn in a red-top vacutainer tube. Note: Serum separators with "clot activators" should not be used for the serum samples.
2.) Allow the blood in the red-top tube to clot at room temperature for 30 minutes.
3.) Centrifuge the clotted blood at room temperature (1000 x g for 10 minutes).
4.) Label "Serum" or "Red-top" on clean screw top-tube(s).
5.) Pipette cell-free supernatant (at least 2 mL) to each labeled tube(s).
6.) Place the tube immediately at -80°C (or on dry ice). Sample must remain deep frozen.
Note: Do not transfer cells with serum. If necessary centrifuge a second time.
Serum must be frozen and U.S. samples must be shipped OVERNIGHT with a minimum of 3 kg (or 6 lbs) dry ice.
- Cryovials should be put in zip lock bags and completely covered in dry ice to keep the sample frozen until it arrives in the lab.
- Delivery: Monday-Friday. NO WEEKEND DELIVERIES
ALL requested information must be provided or testing will not be performed:
Patient information:
-Patient date of birth and gender
-Patient ethnicity and race
-Patients clinical information and family history of kidney disease
Specimen information:
-Patient identifiers (full name, date of birth, sex and medical record number)
-Date of collection
-Sample type - frozen samples must be CLEARLY LABELED as either serum.
-Ordering physician
Sample type must be clearly labeled "serum" and shipped out overnight on at least 5 lbs dry ice (Monday-Thursday).
1.) Follow standard phlebotomy techniques to collect at least 6 cc of whole blood drawn in a red-top vacutainer tube. Note: Serum separators with "clot activators" should not be used for the serum samples.
2.) Allow the blood in the red-top tube to clot at room temperature for 30 minutes.
3.) Centrifuge the clotted blood at room temperature (1000 x g for 10 minutes).
4.) Label "Serum" or "Red-top" on clean screw top-tube(s).
5.) Pipette cell-free supernatant (at least 2 mL) to each labeled tube(s).
6.) Place the tube immediately at -80°C (or on dry ice). Sample must remain deep frozen.
Note: Do not transfer cells with serum. If necessary centrifuge a second time.
Serum must be frozen and U.S. samples must be shipped OVERNIGHT with a minimum of 3 kg (or 6 lbs) dry ice.
- Cryovials should be put in zip lock bags and completely covered in dry ice to keep the sample frozen until it arrives in the lab.
- Delivery: Monday-Friday. NO WEEKEND DELIVERIES
ALL requested information must be provided or testing will not be performed:
Patient information:
-Patient date of birth and gender
-Patient ethnicity and race
-Patients clinical information and family history of kidney disease
Specimen information:
-Patient identifiers (full name, date of birth, sex and medical record number)
-Date of collection
-Sample type - frozen samples must be CLEARLY LABELED as either serum.
-Ordering physician
Transport Temperature
Frozen (-80° C)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen (-80° C): Indefinitely
Refrigerated: Unacceptable
Frozen (-80° C): Indefinitely
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Thawed or unlabeled samples • Serum separator tube
Methodology
Enzyme-Linked Immunosorbent Assay (ELISA)
Setup Schedule
Set up: Mon-Fri; Report available: 4 weeks
Reference Range
Negative
Clinical Significance
Thrombotic microangiopathy (TMA) describes a group of life-threatening multi-systemic diseases characterized by microvascular thrombosis, consumptive thrombocytopenia and microangiopathic hemolytic anemia, often leading to renal failure, cerebral ischemia and end-organ damage. While TMAs are often caused by infections, cancers, pregnancy, drugs, trauma, malignant hypertension and cobalamin deficiency, complement-mediated TMAs, such as atypical hemolytic uremic syndrome (aHUS) are triggered by over-activity of the complement alternative pathway on the cell surface. We have developed a simple, reliable and quick method to detect C3b deposition secondary to fluid-phase complement dysregulation. Images are numerically scored (normal, 1+, 2+, 3+, 4+) using predesignated images.
Indications for screening: Screening is appropriate only for patients with aHUS.
Indications for screening: Screening is appropriate only for patients with aHUS.
